SELLAS Life Sciences Stock Falls 17% After Announcement Of Phase 3 REGAL Trial Milestone

SELLAS Life Sciences (SLS) shares dropped 17% after announcing the Phase 3 REGAL trial for galinpepimut-S reached its 80th event, triggering final analysis. The stock is trading at $10.03, down from $12.17.

Original reporting
Published Oct 28, 2026, 2:54 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 3:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
$SLS
Bearish
high confidence
Mentioned
$SLS
Relevance
8/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$SLSBearishHigh
01

Why it matters

The 80th event milestone signals the trial is moving to final analysis, a key catalyst that triggered a 17% intraday decline.

02

Market read

The trial milestone is a primary catalyst causing a sharp price move, making the news highly relevant for short‑term traders.

03

What to watch

Potential for the company to secure partnership or licensing deals that could offset trial disappointment.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

SELLAS Life Sciences (NASDAQ:SLS) is a small‑cap biotech focused on acute myeloid leukemia therapies.

Company-level read

Ticker impact

$SLSBearishHigh confidence
Context

Phase 3 REGAL trial reached the pre‑specified 80th event, triggering final analysis and a 17% stock drop.

Expected impact

likely pressure as the market prices in the unfavorable trial outcome

Evidence & confidence

The trial event is a material clinical disclosure; the stock already fell 17% on the news, suggesting continued sell pressure.

Market effects

May weigh on other AML/hematology biotech peers as trial data progresses.

Limited to US biotech sector; no broader regional effect.

Minimal global impact beyond niche oncology/hematology investors.

Counterpoint

If the final analysis shows a favorable safety profile, the stock could rebound sharply.

Key entities

  • SELLAS Life Sciences Group, Inc.

    Biotech developer of galinpepimut‑S for AML.

Related articles

$SLSMed

SLS Stock Suffers Worst Rout Since January After $150M Share Sale — But Fresh Filing Has Retail Bulls Saying Sellas Has More Buyout Leverage

Sellas (SLS) shares fell sharply after a $150M share sale, the worst drop since January. The company has rights to a vaccine and is exploring partnerships. Retail traders on Stocktwits remain bullish, citing potential buyout leverage. SLS stock is up 294% year-to-date. Possible buyers mentioned include Merck (MRK) and Johnson & Johnson (JNJ).

$ANTHighAI 8/10

Stock Futures Climb Ahead Of Anthropic's Nasdaq Debut — NVDA, BABA, TTWO, SLS Stocks In Focus

Anthropic priced its IPO at $83 per share, above its $70-$78 range, ahead of its Nasdaq debut under ticker ANT. Intel gained over 4% after securing a customer for its 18A chip process and expanding its Microsoft partnership. Palo Alto Networks surged 10% after beating earnings estimates, while Sellas Life Sciences plunged 18% after a discounted share offering. U.S. equity futures rose ahead of Anthropic's debut.

$NVDAMedAI 8/10

Futures Rise As Huang-less Nvidia Beats And Raises, Gold Crashes Below $3,800

US futures rise as Nvidia (NVDA) reports strong earnings and raises guidance, boosting AI-related stocks. Gold drops below $3,800 after Fed Governor Waller's comments. Nvidia's Q4 revenue guidance is $130B vs. estimates of $125B. Premarket movers include TSLA, GOOGL, AMZN, AAPL, META, AVGO, CRWV, AAOI, BLSH, DLB, LOW, SLS, TTWO, TNDM. Fed policy and economic data releases are in focus.